

CURRICULUM VITAE

Name: Yang Cheng-Kuang M.D.

Chinese Name: 楊晨洸

Date of Birth: April 26 , 1973

Office address: Taichung Veterans General Hospital
Division of Urology, Division of Transplantation , Department
of Surgery 1650 Boulevard Taiwan Taichung, Taiwan, 40705

Telephone: 886-4-23592525ext 5121(Office)

Fax: 886-4-23593160

E-mail: yangck@icloud.com



Education Experience:

1992-1999 M.S Chung Shan Medical University Taichung, Taiwan.

Resident:

Aug 2002-June 2006: Department of Surgery, Taichung Veterans General Hospital

July 2005-June 2006: Chief Resident: Division of Urology, Department of Surgery

Taichung Veterans General Hospital

July 2006-Mar 2008: Clinical Fellowship: Division of Urology, Department of Surgery

Taichung Veterans General Hospital

April 2008-: Attending Surgeon 1. Division of Urology, Department of Surgery

Taichung Veterans General Hospital

Committee member:

1. Taiwan Urology Association Oncology committee
2. Taiwan Urology Association Endolaparoscopy committee
3. Taiwan Urology Association Kidney Transplantation committee
4. Incharge person of central Taiwan Login Center Organ Recruitment Center
5. Asian RARC (robotic cystectomy) Consortium committee

Board Certification:

1. Diplomate of Taiwan Board of Surgery 2004-
2. Diplomate of Taiwan Board of Urology 2006-

Organizations and Societies:

1. Surgical Association Taiwan, R.O.C. 2004-
2. Urological Association Taiwan, R.O.C. 2006-
3. Transplantation Association Taiwan, R.O.C 2008

Research Interest:

1. Urological Oncology (Prostate Cancer , Kidney cancer : renal cell carcinoma and urothelial carcinoma, Bladder cancer, Retroperitoneal Sarcoma, Adrenal tumor)
2. Minimally invasive surgery, Laparoscopic and Robotic assisted Laparoscopic Surgery
3. Kidney Transplantation and Living donor nephrectomy Surgery

National invited speaker & special lecture , live surgery demonstration:

1. 2019-5 AUA WCUS — Minimally invasive radical cystectomy with urinary diversion (invited speaker)
2. 2019-5 Asia Pacific Oncology Symposium — Panel discussion on mRCC treatment
3. 2017-12 Asia Congress of Robotic Surgery — Extended vs Standard lymph node dissection during robotic cystectomy (invited speaker)
4. 2017-11 Hong Kong Urology Oncology Symposium — Robotic cystectomy with urinary diversion , neobladder , Taiwan experience (invited speaker)
5. 2017-8 Urology Association of Asia , 30th anniversary — special lecture , debate on neoadjuvant and adjuvant chemotherapy in bladder cancer (invited speaker)

6. 2017-8 Taiwan Urology Association — 1. robotic and laparoscopic lymph node dissection during cystectomy (speaker) 2. debate on definitive treatment vs active surveillance for low risk prostate cancer (speaker) 3. meet the expert conference of Nephron sparing surgery for RCC (moderator) 4. urinary complication in neobladder for bladder cancer (speaker)
7. 2017-6 Urology bladder cancer symposium (mainland China 廣州) — minimal invasive cystectomy (invited speaker)
8. 2017-5 IRCAD advanced urology course , live surgery demonstration — laparoscopic radical prostatectomy with LN dissection and nerve preservation
9. 2017-3 European Urology Association video presenter
10. 2016-11 Singapor university oncology symposium — urinary diversion in robotic cystectomy (invited speaker)
11. 2016-10 Philippine robotic surgery live demonstration — robotic radical prostatectomy
12. 2016-8 Taiwan Urology Association — 1. meet the expert, nephron sparing surgery for renal cell carcinoma (large tumor , speaker) 2. Pre-operative CT angiography and further image reconstruction for nephron sparing surgery (invited speaker) 3. minimal invasive radical cystectomy (invited speaker)
13. 2016 -7 Urology oncology symposium 杭州 — minimal invasive cystectomy with urinary diversion (invited speaker) , live surgery demonstration - robotic prostatectomy
14. 2016 IRCAD advanced course of urology — live surgery demonstration
15. 2016-3 European Urology Association , asia pacific conference — Robotic prostatectomy in Taiwan (invited speaker)
16. 2016-2 Asia Pacific Prostate Cancer committee conference

2020-2024 Publications papers:

1. Chang, L. W., Hung, S. C., Chen, C. S., Li, J. R., Chiu, K. Y., Wang, S. S., **Yang, C. K.**, Lu, K., Chen, C. C., Wang, S. C., Lin, C. Y., Cheng, C. L., Ou, Y. C., & Yang, S. F. Author Correction: Geriatric nutritional risk index as a prognostic marker for patients with upper tract urothelial carcinoma receiving radical nephroureterectomy. *Sci Rep.* 2024 Dec 6;14(1):30424. doi: 10.1038/s41598-024-81780-6.
2. Wang, C. L., Wang, S. S., Chen, C. S., Hung, S. C., Chen, C. C., **Yang, C. K.**, Li, J. R., Chiu, K. Y., & Lin, C. Y.* Enhancing screening rates for bone health management in prostate cancer patients on androgen deprivation therapy with an automated outpatient system. *Sci Rep.* 2024 Nov 18;14(1):28460. doi: 10.1038/s41598-024-79888-w.
3. Wang, Y. C., Li, J. R., Chen, C. S., Wang, S. S., **Yang, C. K.**, Chiu, K. Y., & Hsu, C. Y. The Long-Term Functional and Oncologic Outcomes of Kidney-Sparing Surgery in Upper Tract Urothelial Carcinoma. *Ann Surg Oncol.* 2024 Nov 16. doi: 10.1245/s10434-024-16523-y. Online ahead of print.
4. Wong, C. H., Ko, I. C., Leung, D. K., Kang, S. H., Kitamura, K., Horie, S., Muto, S., Ohyama, C., Hatakeyama, S., Patel, M., **Yang, C. K.**, Kijvikai, K., Lee, J. Y., Chen, H. G., Zhang, R. Y., Lin, T. X., Lee, L. S., Teoh, J. Y., & Chan, E. Pre-Op Hydronephrosis Predicts Outcomes in Patients Receiving Robot-Assisted Radical Cystectomy. *Cancers (Basel).* 2024 Aug 12;16(16):2826. doi: 10.3390/cancers16162826.
5. Wong, C. H., Ko, I. C., Kang, S. H., Kitamura, K., Horie, S., Muto, S., Ohyama, C., Hatakeyama, S., Patel, M., **Yang, C. K.**, Kijvikai, K., Youl, L. J., Chen, H. G., Zhang, R. Y., Lin, T. X., Lee, L. S., Teoh, J. Y., & Chan, E. Long-Term Outcomes

of Orthotopic Neobladder Versus Ileal Conduit Urinary Diversion in Robot-Assisted Radical Cystectomy (RARC): Multicenter Results from the Asian RARC Consortium. *Ann Surg Oncol*. 2024 Sep;31(9):5785-5793. doi: 10.1245/s10434-024-15396-Epub 2024 May 27.

6. Lai, G. S., Chen, C. S., Cheng, J. C., Li, J. R., **Yang, C. K.**, Lin, C. Y., Hung, S. C., Chiu, K. Y., & Wang, S. S.* Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients. *PLoS One*. 2024 Sep 6;19(9):e0309941. doi: 10.1371/journal.pone.0309941. eCollection 2024.
7. Huang, P. C., Huang, L. H., **Yang, C. K.**, Li, J. R., Chen, C. S., Wang, S. S., Chiu, K. Y., Ou, Y. C.,* & Lin, C. Y. *Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective. *PLoS One*. 2024 Aug 7;19(8):e0306900. doi: 10.1371/journal.pone.0306900. eCollection 2024.
8. Lin, C. Y., Wang, C. L., **Yang, C. K.**, Li, J. R., Chen, C. S., Chiu, K. Y., Lin, C. H., & Wang, S. S. The impact of novel hormonal agents on fracture risk in prostate cancer patients: a nationwide population-based cohort study. *Sci Rep*. 2024 Nov 4;14(1):26696. doi: 10.1038/s41598-024-73598-z.
9. Yang, L. Y., Li, J. R., Chen, C. S., Cheng, C. L., Hung, S. C., Chiu, K. Y., **Yang, C. K.**, Hsu, C. Y., & Wang, S. S.* Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer. *Front Pharmacol*. 2024 Mar 26;15:1281654. doi: 10.3389/fphar.2024.1281654. eCollection 2024.
10. Lai, G. S., Li, J. R., Wang, S. S., Chen, C. S., **Yang, C. K.**, Lin, C. Y., Hung, S. C., Chiu, K. Y., & Yang, S. F. Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database. *PLoS One*. 2024 Mar 28;19(3):e0299102. doi: 10.1371/journal.pone.0299102. eCollection 2024.
11. Huang, L. H., Chen, C. S., Li, J. R., Chiu, K. Y., Wang, S. S., **Yang, C. K.**, Cheng, C. L., Lin, C. C., & Ou, Y. C. The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy. *BMC Cancer*. 2024 Feb 22;24(1):247. doi: 10.1186/s12885-024-12010-5.
12. Chen, Y. W., Yang, H. C., Liao, P. C., Chen, C. S., **Yang, C. K.**, & Yang, L. Y. Malfunction endostapler trapped on renal vein - Nightmare scenario for surgeon. *Urol Case Rep*. 2024 Feb 8;53:102671. doi: 10.1016/j.eucr.2024.102671. eCollection 2024 Mar. (Case report)
13. Chen, C. Y., Chang, C. H., Yang, C. R., Hsieh, K. L., Tsing, W. H., Chen, I. A., Lin, J. T., Huang, C. Y., Hong, J. H., Tseng, J. S., Lin, W. R., Tsai, Y. C., Wu, S. Y., Shen, C. H., Cheong, I. S., Chen, C. S., **Yang, C. K.**, Jiang, Y. H., Tsai, C. Y., . . . Lee, H. Y. Prognostic factors of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*. 2024 Jan 10;42(1):22. doi: 10.1007/s00345-023-04700-9.
14. Yang, H. C., Hsieh, H. C., Liao, P. C., Chang, L. W., Hu, J. C., Hung, S. C., Lin, C. Y., Wang, S. C., Chen, C. C., **Yang, C. K.**, Wang, S. S., Chen, C. S., Lu, K., Li, J. R., Cheng, C. L., & Chiu, K. Y. *Nephroscope-assisted single trocar peritoneal dialysis catheter insertion improves catheter survival compared with laparoscopic technique: Ten-year experience of a single-center. *Asian J Surg*. 2024 Jan;47(1):303-309. doi: 10.1016/j.asjsur.2023.08.143. Epub 2023 Sep 7.
15. Lai, G. S., Li, J. R., Wang, S. S., Chen, C. S., **Yang, C. K.**, Lin, C. Y., Hung, S. C., Chiu, K. Y., & Yang, S. F. Real world treatment sequences and outcomes for metastatic renal cell carcinoma. *PLoS One*. 2023 Nov 22;18(11):e0294039. doi: 10.1371/journal.pone.0294039. eCollection 2023.
16. Lai, G. S., Li, J. R., Wang, S. S., Chen, C. S., **Yang, C. K.**, Lin, C. Y., Hung, S. C., Ho, H. C., Ou, Y. C., Chiu, K. Y., & Yang, S. F. Influence of Surgical Complications on Outcomes in Kidney Transplantation Patients. *In Vivo* . 2023

- Nov-Dec*;37(6):2796-2802. doi: 10.21873/invivo.13392.
17. Ni, H. F., Li, J. R., Wang, S. S., Hung, S. C., Yang, C. K., Chen, C. S., & Chiu, K. Y. Prognostic Factors of Extramammary Paget's Disease: A Retrospective Study at a Medical Center in Taiwan. *In Vivo*. 2023 *Nov-Dec*;37(6):2786-2791. doi: 10.21873/invivo.13390.
 18. Wang, B. R., Ou, Y. C., Huang, L. H., Lu, C. H., Weng, W. C., Yang, C. K., Hsu, C. Y., Lin, Y. S., **Chang, Y. K.**, & Tung, M. C. Robotic partial nephrectomy for renal tumor: The pentafecta outcomes of a single surgeon experience. *Asian J Surg*. 2023 *Sep*;46(9):3587-3592. doi: 10.1016/j.asjsur.2023.05.140.
 19. Chiou, J. K., Chang, L. W., Li, J. R., Wang, S. S., **Yang, C. K.**, Chen, C. S., Lu, K., Cheng, C. L., Chiu, K. Y., & Hung, S. C. Metastasectomy Improves Overall Survival in Metastatic Renal Cell Carcinoma: A Retrospective Cohort Study. *Anticancer Res*. 2023 *Jul*;43(7):3193-3201. doi: 10.21873/anticancer.16493.
 20. Lin, C. Y., Wang, C. L., Wang, S. S., **Yang, C. K.**, Li, J. R., Chen, C. S., Hung, S. C., Chiu, K. Y., Cheng, C. L., Ou, Y. C., & Yang, S. F. WWOX Polymorphisms as Predictors of the Biochemical Recurrence of Localized Prostate Cancer after Radical Prostatectomy. *Int J Med Sci*, 2023 *May 21*;20(7):969-975. doi: 10.7150/ijms.84364.
 21. Yen, T. H., Wang, S. S., **Yang, C. K.**, Lu, K., Chen, C. S., Cheng, C. L., Hung, S. C., Chiu, K. Y., Chen, C. P., Yang, C. R., & Li, J. R. Risk analysis of subsequent therapies after first-line chemotherapy in advanced testicular cancer patients. *J Chin Med Assoc*, 2023 *Jul 1*;86(7):646-652. doi: 10.1097/JCMA.0000000000000938. Epub 2023 Jul.
 22. **Yang, C. K.**, Yang, C. R., Ou, Y. C., Cheng, C.L., Ho, H.C., Chiu, K.Y*., Wang, S.S., Li, J.R., Chen, C.S., Hung, C.F., Chen, C.C., Wang, S.C., Lin, C.Y., & Hung, S.C. Prostate-specific antigen density and preoperative MRI findings as predictors of biochemical recurrence in high-risk and very high-risk prostate cancer. *Oncol Lett*, 2023 *May 18*;26(1):284. doi: 10.3892/ol.2023.13870.
 23. Yang, H. C., Chang, L. W., Li, J. R., Wang, S. S., **Yang, C. K.**, Chen, C. S., Lu, K., Chen, C. C., Wang, S. C., Lin, C. Y., Cheng, C. L., Ou, Y. C., Chiu, K. Y., & Hung, S. C. Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. *Anticancer Res*. 2023 *Apr*;43(4):1809-1816.
 24. Chang, L. W., Hung, S. C., Chen, C. S., Li, J. R., Chiu, K. Y., Wang, S. S., **Yang, C. K.**, Lu, K., Chen, C. C., Wang, S. C., Lin, C. Y., Cheng, C. L., Ou, Y. C., & Yang, S. F. Geriatric nutritional risk index as a prognostic marker for patients with upper tract urothelial carcinoma receiving radical nephroureterectomy. *Sci Rep* . 2023 *Mar*; 13(1):4554.
 25. Li, J. R., Wang, S. S., Lu, K., Chen, C. S., Cheng, C. L., Hung, S. C., Chiu, K. Y., Hsu, C. Y., & **Yang, C. K.*** First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study. *Anticancer Res*. 2023 *Mar*;43(3):1331-1339.
 26. **Yang, C. K.**, Cha, T. L., Chang, Y. H., Huang, S. P., Lin, J. T., Wang, S. S., Huang, C. Y*., & Pang, S. T.* Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use. *J Formos Med Assoc*. 2023 *Apr*;122(4):299-308. doi: 10.1016/j.jfma.2022.12.008.
 27. Chang, L. W., Wang, S. S., **Yang, C. K.**, Lu, K., Chen, C. S., Cheng, C. L., Hung, S. C., Chiu, K. Y., Hsu, C. Y., & Li, J. R. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia. *Anticancer Res*, 2023 *Jan*;43(1): 485-491.
 28. Lee, A. Y., Allen, J. C., Jr., Teoh, J. Y., Kang, S. H., Patel, M. I., Muto, S., **Yang,**

- C. K.**, Hatakeyama, S., Zhang, R., Kijvikai, K., Chen, H., Ohyama, C., Horie, S., Chan, E. S., & Lee, L. S. Predicting perioperative outcomes of robot-assisted radical cystectomy: Data from the Asian Robot-Assisted Radical Cystectomy Consortium. *Int J Urol.* 2022 Sep;29(9):1002-1009. doi: 10.1111/iju.14937. Epub 2022 May 25.
29. Wu, K. H., Chang, C. H., Wu, H. C., Huang, S. K., Liu, C. L., **Yang, C. K.**, Li, J. R., Tseng, J. S., Lin, W. R., Yu, C. C., Lo, C. W., Huang, C. Y., Chen, C. H., Tsai, C. Y., Cheng, P. Y., Jiang, Y. H., Lee, Y. K., Chen, Y. T., Yeh, T. C., . . . Ke, H. L. Oncologic impact of delay between diagnosis and radical nephroureterectomy. *Front Oncol.* 2022 Dec 14;12:1025668. <https://doi.org/10.3389/fonc.2022.1025668>
 30. Hsieh, H. C., Wang, C. L., Chen, C. S., **Yang, C. K.**, Li, J. R., Wang, S. S., Cheng, C. L., Lin, C. Y.*, & Chiu, K. Y.* The prognostic impact of lymph node dissection for clinically node-negative upper urinary tract urothelial carcinoma in patients who are treated with radical nephroureterectomy. *PLoS One.* 2022 Dec;17(12):e0278038.
 31. Li, J. R., Wang, S. S., Chen, C. S., **Yang, C. K.**, Lu, K., Cheng, C. L., Hung, S. C., Chen, S. Y., Hsu, C. Y., & Chiu, K. Y. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study. *Anticancer Res.* 2022 Oct;42(10):4857-4866.
 32. Lin, K. Y., Chen, L., Hung, S. W., Hung, S. C., **Yang, C. K.**, Chen, C. J., & Chiu, K. Y. A para-aortic malignant melanotic nerve sheath tumor mimicking a gastrointestinal stromal tumor: a rare case report and review of literature. *BMC Surg.* 2022 Jul; 22(1):293. <https://doi.org/10.1186/s12893-022-01727-4>
 33. Lai, G. S., Li, J. R., Wang, S. S., **Yang, C. K.**, Hung, S. C., Cheng, C. L., Ou, Y. C., Chiu, K. Y. Tumor Size Significantly Affects Prognosis in Pathological T3a Renal Cell Carcinoma. *Anticancer Res.* 2022 Apr;42(4): 2185-2191. doi: 10.21873/anticancerres.15701
 34. Chen, C. S., Li, J. R., **Yang, C. K.**, Cheng, C. L., Yang, C. R., Ou, Y. C., . . . Wang, S. S. Significant predictors of contralateral upper tract recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. *Int J Urol.* 2021 Oct; 29(1): 69-75.
 35. Hung, S. C., Chang, L. W., Li, J. R., Wang, S. S., **Yang, C. K.**, Chen, C. S., . . . Chiu, K. Y. Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. *In Vivo.* 2021 Nov-Dec;35(6):3509-3519.
 36. Teoh, J. Y., Chan, E. O., Kang, S. H., Patel, M. I., Muto, S., **Yang, C. K.**, Hatakeyama, S., Chow, T. S., Mok, A., Zhang, R., Kijvikai, K., Lee, L. S., Chen, H., Ohyama, C., Horie, S., & Chan, E. S. Perioperative Outcomes of Robot-Assisted Radical Cystectomy with Intracorporeal Versus Extracorporeal Urinary Diversion. *Ann Surg Oncol.* 2021 Dec;28(13):9209-9215. doi: 10.1245/s10434-021-10295-5. Epub 2021 Jun 21.
 37. Hsieh, P. Y., Hung, S. C., Li, J. R., Wang, S. S., **Yang, C. K.**, Chen, C. S., . . . Chiu, K. Y. The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis. *Urol Oncol.* 2021 Jul;39(7): 422-430.
 38. Lai, G. S., Li, J. R., Wang, S. S., Chen, C. S., **Yang, C. K.**, Hung, S. C., . . . Chiu, K. Y. Prognostic Evaluation of the Site of Invasion in Pathological Stage T3a Renal Cell Carcinoma. *In Vivo.* 2021 Mar-Apr;35(2):1083-1089.
 39. Hu, J. C., Wang, S. S., Chou, Y. E., Chiu, K. Y., Li, J. R., Chen, C. S., Hung, S. C., **Yang, C. K.**, Ou, Y. C., Cheng, C. L., Lin, C. Y., Yang, S. F. Associations between LncRNA MALAT1 Polymorphisms and Lymph Node Metastasis in Prostate Cancer. *Diagnostics (Basel),* 2021 Sep 16;11(9):1692. doi:

10.3390/diagnostics11091692.

40. Chen, Y. T., Yu, C. C., Yeh, H. C., Lee, H. Y., Jiang, Y. H., Lee, Y. K., Kuei, C. H., Wu, C. C., Huang, C. Y., Lin, W. Y., **Yang, C. K.***, Tsai, Y. C.* Endoscopic management versus radical nephroureterectomy for localized upper tract urothelial carcinoma in a high endemic region. *Sci Rep.* 2021 Feb 17;11(1):4040. doi: 10.1038/s41598-021-83495-4. 共同通訊作者
41. Chen, C. S., Lin, C. Y., Wang, C. L., Wang, S. S., Li, J. R., **Yang, C. K.**, Cheng, C. L., Chiu, K. Y.,* Yang, S. F. * Association between lymphovascular invasion and oncological outcome in node-negative upper tract urothelial carcinoma with different stage. *Urol Oncol.* 2021 Feb;39(2):132.e13-132.e26.Epub 2020 Sep 6.
42. Hsu, C. T., Wen, M. C., Chiu, H. F., Tsai, S. F., Yu, T. M., **Yang, C. K.**, . . . Chen, C. H.* Ongoing donor-transmitted diabetic kidney disease in kidney transplant recipients with fair sugar control: a single center retrospective study. *BMC Nephrol.* 2020 Nov 3;21(1):458. doi: 10.1186/s12882-020-02132-w.
43. Hu, J. C., Lin, C. Y., Wang, S. S., Chiu, K. Y., Li, J. R., Chen, C. S., Hung, S. C., **Yang, C. K.**, Ou, Y. C., Cheng, L. W., Yang, S. F. * Impact of H19 Polymorphisms on Prostate Cancer Clinicopathologic Characteristics. *Diagnostics (Basel).* 2020 Aug 31;10(9):656. doi: 10.3390/diagnostics10090656.
44. Lai, G. S., Li, J. R., Wang, S. S., Chen, C. S., **Yang, C. K.**, Hung, S. C., . . . Chiu, K. Y. * Prognostic Evaluation of the Site of Invasion in Pathological Stage T3a Renal Cell Carcinoma. *In Vivo.* 2021 Mar-Apr;35(2):1083-1089.
45. Chang, L. W., Hung, S. C., Li, J. R., Chiu, K. Y., **Yang, C. K.**, Chen, C. S., . . . Wang, S. S. Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel. *Front Pharmacol.* 2021 Jan 25;11:601513. doi: 10.3389/fphar.2020.601513. eCollection 2020.
46. Chen, C. S., Li, J. R., Wang, S. S., **Yang, C. K.**, Cheng, C. L., Yang, C. R., Ou, Y. C., Ho, H. C., Lin, C. Y., Hung, S. C., Chen, C. C., Wang, S. C., Chiu, K. Y.* and Yang, S. F.* Tumor Multifocality is a Significant Risk Factor of Urinary Bladder Recurrence after Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma: A Single-Institutional Study. *Diagnostics (Basel).* 2020 Apr 3;10(4):201. doi: 10.3390/diagnostics10040201.
47. Lai, G. S., Li, J. R., Wang, S. S., Chen, C. S., **Yang, C. K.**, Hung, S. C., . . . Chiu, K. Y. Survival Analysis of Pathological T3a Upstaging in Clinical T1 Renal Cell Carcinoma. *In Vivo.* 2020 Mar-Apr;34(2):799-805. doi: 10.21873/invivo.11841.
48. Lai, G.S., Hung, S.C., Chang, L.W., Wang, S.S., Li, J.R., Chen, C.S., **Yang, C.K.**, Cheng, C.L., Ou, Y.C., Ho, H.C. and Chiu, K.Y.* Renal volume matters: Assessing the association between excisional volume loss and renal function after partial nephrectomy. *Asian J Surg.* 2020 Jan;43(1):257-264.